Authors

Maryam Abooali, Medway School of Pharmacy
Stephanie Schlichtner, Heidelberg University of Education
Xi Lei, Medway School of Pharmacy
Nijas Aliu, University of Bern
Sabrina Ruggiero, University of Bern
Sonia Loges, Heidelberg University of Education
Martin Ziegler, Heidelberg University of Education
Franziska Hertel, Heidelberg University of Education
Anna-Lena Volckmar, University Hospital Heidelberg and German Consortium for Translational Cancer Research (DKTK)
Albrecht Stenzinger, University Hospital Heidelberg and German Consortium for Translational Cancer Research (DKTK)
Petros Christopoulos, University Hospital Heidelberg and German Consortium for Translational Cancer Research (DKTK)
Michael Thomas, University Hospital Heidelberg and German Consortium for Translational Cancer Research (DKTK)
Elena Klenova, University of Essex
N Helge Meyer, University of Oldenburg
Stergios Boussios, University of Kent
Nigel Heaton, King's College Hospital NHS Foundation Trust
Yoh Zen, King's College Hospital NHS Foundation Trust
Ane Zamalloa, King's College Hospital NHS Foundation Trust
Shilpa Chokshi, Peninsula Medical School
Luca Urbani, King's College London
Sophie Richard, King's College London
Kavitha Kirubendran, King's College London
Rohanah Hussain, Beamline 23, Diamond Light Source, Didcot, UK.
Giuliano Siligardi, Beamline 23, Diamond Light Source, Didcot, UK.
Dietmar Cholewa, University of Bern
Steffen M Berger, University of Bern
Inna M Yasinska, Medway School of Pharmacy
Elizaveta Fasler-Kan, University of Bern
Vadim V Sumbayev, Medway School of Pharmacy

ORCID

Abstract

V-domain Ig-containing suppressor of T cell activation (VISTA) is a unique immune checkpoint protein, which was reported to display both receptor and ligand activities. However, the mechanisms of regulation of VISTA activity and functions by factors of tumour microenvironment (TME) remain unclear and understanding these processes is required in order to develop successful personalised cancer immunotherapeutic strategies and approaches. Here we report for the very first time that VISTA interacts with another immune checkpoint protein galectin-9 inside the cell most likely facilitating its interaction with TGF-β-activated kinase 1 (TAK1). This process is required for protection of lysosomes, which is crucial for many cell types and tissues. We found that VISTA expression can be differentially controlled by crucial factors present in TME, such as transforming growth factor beta type 1 (TGF-β) and hypoxia as well as other factors activating hypoxic signalling. We confirmed that involvement of these important pathways modulated by TME differentially influences VISTA expression in different cell types. These networks include: TGF-β-Smad3 pathway, TAK1 (TGF-β-activated kinase 1) or apoptosis signal-regulating kinase 1 (ASK1)-induced activation of activating transcription factor 2 (ATF-2) and hypoxic signalling pathway. Based on this work we determined the five critical functions of VISTA and the role of TME factors in controlling (modulating or downregulating) VISTA expression.

Publication Date

2025-04-28

Publication Title

Cancer Letters

Volume

616

ISSN

0304-3835

Keywords

Tumor Microenvironment/immunology, Humans, MAP Kinase Kinase Kinases/metabolism, B7 Antigens/metabolism, Signal Transduction, Cell Line, Tumor, Neoplasms/immunology

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

First Page

217581

Last Page

217581

Share

COinS